Company: PCRX
Filing Date: 2025-07-10
Form Type: 8-K
Source: 0001396814-25-000093
Chunk: 2

Company: Pacira BioSciences, Inc.
Filing Date: 2025-07-10
Form: 8-K
Item: Item 7.01
Chunk 2
---
 with acquisitions, such as the risk that the businesses will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; the Company’s manufacturing and supply chain, global and U. S. economic conditions (including inflation and rising interest rates), and the Company’s business, including the Company’s revenues, financial condition, cash flow and results of operations; the success of the Company’s sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and iovera°; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera°; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera° and the Company’s ability to serve those markets; the Company’s plans to expand the use of EXPAREL, ZILRETTA and iovera° to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA

and iovera°; the commercial success of EXPAREL, ZILRETTA and iovera°; the related timing and success of U. S. Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; the Company’s plans to evaluate, develop and pursue additional product candidates utilizing the Company’s proprietary multivesicular liposome (“pMVL”) drug delivery technology; the approval of the commercialization of the Company’s products in other jurisdictions; clinical trials in support of an existing or potential pMVL-based product; the Company’s commercialization and marketing capabilities; the Company’s ability to successfully complete capital projects; the outcome of any litigation; the recoverability of the Company’s deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the Company; the anticipated funding or benefits of the Company’s share repurchase program; and factors discussed in the “ Risk Factors” of the Company’s most recent Annual Report on Form 10-K and in other filings that the Company periodically makes with the Securities and Exchange Commission (the “ SEC”). In addition, the forward-looking statements included in this Current Report on Form 8-K represent the Company’s views as of the date of this Current Report on Form 8-K. Important factors could cause actual results